SCHEMBL2034985

SCHEMBL2034985

O=S(=O)(Nc1cc(Cl)c(S(=O)(=O)c2ccc3ccccc3c2)c(Cl)c1)c1ccc(Cl)nc1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.56
GAA P10253 2/20 0.48
PIK3CB P42338 1/20 0.47
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 2/20 0.46
ATM Q13315 1/20 0.45
CCR2 P41597 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
HPGD P15428 1/20 0.44
PKM P14618 1/20 0.43
PKLR P30613 1/20 0.43
PGR P06401 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2031882 0.86 PPARG (0.52) PPARGGAAALDH1A1SMN1; SMN2LMNA
SCHEMBL2028748 0.82 PPARG (0.49) PPARGGAAPIK3CBALDH1A1SMN1; SMN2
SCHEMBL2037866 0.78 ALDH1A1 (0.46) PPARGGAAALDH1A1SMN1; SMN2LMNA
SCHEMBL2036828 0.77 PPARG (0.45) PPARGGAAALDH1A1SMN1; SMN2LMNA
SCHEMBL2568163 0.75 GAA (0.64) GAAALDH1A1LMNACCR2MEN1
SCHEMBL2034434 0.73 PPARG (0.59) PPARGGAAALDH1A1SMN1; SMN2LMNA
SCHEMBL17849572 0.73 PKM (0.63) PPARGGAAALDH1A1SMN1; SMN2LMNA
SCHEMBL16187975 0.73 ATM (0.58) PPARGGAAALDH1A1SMN1; SMN2LMNA
SCHEMBL12585096 0.72 ACLY (0.50)
SCHEMBL16529720 0.72 ALDH1A1 (0.53) GAAALDH1A1LMNACCR2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968567-B2 Compounds for the modulation of PPARγ activity AMGEN INC. (US) 2011-06-28 US disclosed
US-7968567-B2 Compounds for the modulation of PPARγ activity AMGEN INC. (US) 2011-06-28 US disclosed
US-7968567-B2 Compounds for the modulation of PPARγ activity AMGEN INC. (US) 2011-06-28 US disclosed
US-20100113522-A1 COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY AMGEN INC. (US) 2010-05-06 US disclosed
US-20100113522-A1 COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY AMGEN INC. (US) 2010-05-06 US disclosed
US-20100113522-A1 COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY AMGEN INC. (US) 2010-05-06 US disclosed
US-7626033-B2 Compounds for the modulation of PPARγ activity AMGEN INC. (US) 2009-12-01 US disclosed
US-7626033-B2 Compounds for the modulation of PPARγ activity AMGEN INC. (US) 2009-12-01 US disclosed
US-20060264481-A1 Therapeutic modulation of PPARgamma activity AMGEN INC. (US) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264481-A1 Therapeutic modulation of PPARgamma activity PPARG, PPARA, PPARD PPARG 1/4885GAA 1364/4885PIK3CB 1816/4885
US-20100113522-A1 COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY PPARG, PPARA, PPARD PPARG 1/4885GAA 402/4885PIK3CB 717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.